Rationale: Cerebral Methyl-CpG binding Protein 2 (MeCP2) is involved in several psychiatric disorders that are concomitant with cognitive dysfunction. However, the regulatory function of striatal MeCP2 and its association with Alzheimer's disease (AD) has been largely neglected due to the absence of amyloid plaque accumulation in the striatal region until the later stages of AD progression. Considerable evidence indicates that neuropsychiatric symptoms related to cognitive decline are involved with striatal dysfunction. To this respect, we investigated the epigenetic function of striatal MeCP2 paralleling the pathogenesis of AD. Methods: We investigated the brain from amyloid precursor protein (APP)/presenilin1 (PS1) transgenic mice an...
Epigenetics is emerging as the missing link among genetic inheritance, environmental influences, and...
INTRODUCTION: Different animal models for Alzheimer disease (AD) have been designed to support the h...
Presented at: Society for Neuroscience annual meeting in New Orleans, LA Oct 12-17, 2012 Alzheimer’s...
The synaptic changes underlying the onset of cognitive impairment in Alzheimer’s disease (AD) are po...
Alzheimer\u27s disease (AD) is characterized by anterograde amnesia followed by a progressive declin...
5XFAD is an early-onset mouse transgenic model of Alzheimer disease (AD). Up to now there are no stu...
Introduction: Different animal models for Alzheimer disease (AD) have been designed to support the h...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, F...
Alzheimer's disease (AD) is a consequence of degenerative brain pathology with amyloid plaque deposi...
Mutations in the amyloid precursor protein (APP) gene inducing abnormal processing and deposition of...
Alzheimer's disease (AD) is characterized by amyloid (Aβ) protein aggregation and neurofibrillary ta...
International audienceAlzheimer's disease (AD) is the most frequent form of dementia in the elderly ...
Summary: Amyloid precursor protein (APP) and its metabolites play key roles in Alzheimer’s disease (...
BACKGROUND: Autosomal dominant Alzheimer's disease (ADAD) is distinguished from late-onset AD by ear...
The amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of Alzheimer's disease (AD) has pro...
Epigenetics is emerging as the missing link among genetic inheritance, environmental influences, and...
INTRODUCTION: Different animal models for Alzheimer disease (AD) have been designed to support the h...
Presented at: Society for Neuroscience annual meeting in New Orleans, LA Oct 12-17, 2012 Alzheimer’s...
The synaptic changes underlying the onset of cognitive impairment in Alzheimer’s disease (AD) are po...
Alzheimer\u27s disease (AD) is characterized by anterograde amnesia followed by a progressive declin...
5XFAD is an early-onset mouse transgenic model of Alzheimer disease (AD). Up to now there are no stu...
Introduction: Different animal models for Alzheimer disease (AD) have been designed to support the h...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, F...
Alzheimer's disease (AD) is a consequence of degenerative brain pathology with amyloid plaque deposi...
Mutations in the amyloid precursor protein (APP) gene inducing abnormal processing and deposition of...
Alzheimer's disease (AD) is characterized by amyloid (Aβ) protein aggregation and neurofibrillary ta...
International audienceAlzheimer's disease (AD) is the most frequent form of dementia in the elderly ...
Summary: Amyloid precursor protein (APP) and its metabolites play key roles in Alzheimer’s disease (...
BACKGROUND: Autosomal dominant Alzheimer's disease (ADAD) is distinguished from late-onset AD by ear...
The amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of Alzheimer's disease (AD) has pro...
Epigenetics is emerging as the missing link among genetic inheritance, environmental influences, and...
INTRODUCTION: Different animal models for Alzheimer disease (AD) have been designed to support the h...
Presented at: Society for Neuroscience annual meeting in New Orleans, LA Oct 12-17, 2012 Alzheimer’s...